Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced a next-day disclosure return dated 29 April 2026 detailing a further on-market share repurchase.

The company bought back 32,700 H shares on 29 April 2026 at prices ranging between HKD 29.06 and HKD 31.00 per share, representing a volume-weighted average repurchase price of HKD 29.74. The aggregate consideration was approximately HKD 0.97 million.

Following the transaction, issued shares (excluding treasury shares) declined by 0.024 % from 135.81 million to 135.77 million. Treasury shares increased from 413,400 to 446,100, while total issued shares remained unchanged at 136.22 million.

The repurchase forms part of the mandate approved on 12 February 2026, which authorises Hanx Biopharmaceuticals to buy back up to 13.62 million shares. To date, 446,100 shares have been repurchased under this mandate, equivalent to 0.33 % of the issued share capital on the mandate date.

In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 29 May 2026. Directors confirmed that all repurchase procedures complied with the Main Board Listing Rules and relevant legal requirements.